

Drug-Induced AIH due to HemoHIM in a 28-Year-Old Pregnant Woman

Colleen Long, MD¹, Jason John, MD², Michael Kriss, MD³

¹ Internal Medicine Residency Program, ² Division of Hospital Medicine, ³ Division of Gastroenterology and Hepatology Department of Medicine, School of Medicine, University of Colorado Denver, Aurora, Colorado, USA

Background

- ☐ Drug-induced autoimmune hepatitis (DIAIH) is a pathologic immune response against proteins in the liver triggered in susceptible individuals by drugs or herbal remedies¹
- ☐ While any supplement can cause idiosyncratic hepatotoxicity, up to 16% of drug-induced liver injuries are attributable to over-thecounter supplements¹
- ☐ There are limited data on herbal medicine-related hepatotoxicity, leading to underreporting in registry tools, such as NIH LiverTox, which are important for disease recognition and clinical management
- ☐ This topic is particularly understudied in pregnant patients, with most current clinical information coming from case reports.
- ☐ While use of supplements is common during pregnancy, there is limited information regarding their safety and impact on both maternal and fetal health

Case Presentation- History of Present Illness

HPI:

A previously healthy G4P2A1 28-year-old presented at 5 weeks of pregnancy with right upper quadrant pain and fevers

- ☐ Patients prior 2 pregnancies complicated by intrahepatic cholestasis of pregnancy requiring early delivery at 38 weeks
- ☐ Initial labs demonstrated hyperbilirubinemia and severe transaminase elevation
- ☐ Viral hepatitis panel negative and acetaminophen level undetectable
- ☐ MRCP revealed thickened gallbladder wall with normal intrahepatic ducts and normal common bile duct consistent with cholecystitis
- ☐ Patient presumed to have acute cholecystitis and underwent laparoscopic cholecystectomy
- ☐ Despite this procedure, liver enzymes continued to worsen and she developed signs of synthetic dysfunction requiring transfer to University of Colorado Hospital for further evaluation

Physical Exam Upon Transfer:


- □ BP 92/52, P 96, T 38.8 C, R 20
- ☐ A&O x3, no focal
- No asterixis
- ☐ Scleral Icterus and jaundice
- ☐ Abdomen soft, non-distended, non-tender to palpation, well healing scars in RUQ
- ☐ Rash (blanching, diffuse, covering most of BSA) see image 2

Objective Data

- ☐ AST 2893
- □ ALT 2664 ☐ TBili 2.6
- ☐ Alk Phos 460
- □ INR 1.3
- ☐ Hepatitis serologies negative for: acute HAV, HBV, and HCV.
- ☐ EBV, CMV antibodies negative.
- ☐ HSV PCR negative.
- ☐ APAP undetectable
- □ Laboratory evidence of AIH: ANA +, Anti-Mi+ 34.5 (ref < 25), U1-RNP/RNA-A68 2.4, Chromatin Abs 1.6

Pathology

Image 1 Liver biopsy showed acute-on-chronic hepatitis with an abundance of plasma cells (A) and dense portal inflammation (B) most consistent with autoimmune hepatitis v DILI.6






Image 2 Diffuse blanchable rash





Clinical Course

- ☐ Serology and pathology results demonstrated evidence of autoimmune hepatitis (AIH) with possible drug-induced liver injury
- ☐ Prior to admission, patient had started taking herbal supplement HemoHIM with purported immune support; thought to be possible driver of liver injury
- ☐ As AIH often presents during pregnancy, unclear if this presentation represented DIAIH or AIH
- ☐ Patient started on 60 mg prednisolone with subsequent clinical and laboratory improvement
- ☐ Despite maternal improvement, the patient suffered spontaneous abortion early in the treatment course
- ☐ Given concern for possible AIH and sluggish normalization of LFTs, started on azathioprine but self-discontinued after 7 months.
- ☐ Liver enzymes remained stable off azathioprine and was thus not restarted

Discussion

- ☐ Current estimates report DIAIH accounts for 2-18% of AIH cases^{3,4} and 2.9-8.8% of DILI ³
- ☐ This case demonstrates the diagnostic challenges of DIAIH in prenatal patients
- ☐ DIAIH lacks pathognomonic features distinct from AIH given similar autoimmune serologic profiles and pathological features³
- ☐ There is an absence of specific diagnostic criteria and no consensus on the adequate terminology for the various clinical patterns of DIAIH4
- ☐ Some important distinguishing factors in AIH v DIAIH include:
- ☐ Immuno-allergic presentation with skin rash, fever, lymphadenopathy, and eosinophilia favor DIAIH, as it may occur in up to 30% of DIAIH⁴
- ☐ Frequently, DIAIH resolves with discontinuation of the offending agent. However, if there is no clinical improvement, steroids with or without immunosuppressive agents are often started (as seen in this case)
- ☐ In general, DIAIH requires a significantly shorter treatment course with steroids than does AIH to achieve remission (2 mo vs 16.8 mo)⁵

- . Zucker, Kelly DO¹; Fung, Brian M. MD¹; Haddad, Nael MD²; Mehta, Shivang MD¹
- The American Journal of Gastroenterology: October 2021 Volume 116 Issue p S1102 doi:
- 2. Kamath P, Kamath A, Ullal SD. Liver injury associated with drug intake during pregnancy. World J Hepatol. 2021;13(7):747-
- 3. de Boer YS, Kosinski AS, Urban TJ, Zhao Z, Long N, Chalasani N, Kleiner DE, Hoofnagle JH Drug-Induced Liver Injury Network. Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury. Clin Gastroenterol Hepatol. 2017;15:103—
- 4. Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American
- Association for the Study of Liver Diseases. Hepatology. 2020;72:671–722. 5. Martínez-Casas OY, Díaz-Ramírez GS, Marín-Zuluaga JI, Muñoz-Maya O, Santos O, Donado-Gómez JH, Restrepo-Gutiérrez
- JC. Differential characteristics in drug-induced autoimmune hepatitis. JGH Open. 2018;2:97–104 6. Kleiner DE. Recent Advances in the Histopathology of Drug-Induced Liver Injury. Surg Pathol Clin. 2018 Jun;11(2):297-311. doi: 10.1016/j.path.2018.02.009. PMID: 29751876; PMCID: PMC5953206.